Annual Accounts Payable
$2.05 M
-$343.00 K-14.33%
31 December 2023
Summary:
Lineage Cell Therapeutics annual accounts payable is currently $2.05 million, with the most recent change of -$343.00 thousand (-14.33%) on 31 December 2023. During the last 3 years, it has fallen by -$561.00 thousand (-21.49%). LCTX annual accounts payable is now -42.14% below its all-time high of $3.54 million, reached on 31 December 2021.LCTX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$1.60 M
-$789.00 K-33.04%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly accounts payable is currently $1.60 million, with the most recent change of -$789.00 thousand (-33.04%) on 30 September 2024. Over the past year, it has dropped by -$831.00 thousand (-34.20%). LCTX quarterly accounts payable is now -64.83% below its all-time high of $4.55 million, reached on 31 March 2016.LCTX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.3% | -34.2% |
| 3 y3 years | -21.5% | -53.8% |
| 5 y5 years | -13.1% | -20.4% |
LCTX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -42.1% | at low | -54.9% | at low |
| 5 y | 5 years | -42.1% | at low | -54.9% | at low |
| alltime | all time | -42.1% | +1950.0% | -64.8% | +1499.0% |
Lineage Cell Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.60 M(-33.0%) |
| June 2024 | - | $2.39 M(+8.0%) |
| Mar 2024 | - | $2.21 M(+7.9%) |
| Dec 2023 | $2.05 M(-14.3%) | $2.05 M(-15.6%) |
| Sept 2023 | - | $2.43 M(+11.1%) |
| June 2023 | - | $2.19 M(-27.1%) |
| Mar 2023 | - | $3.00 M(+25.4%) |
| Dec 2022 | $2.39 M(-32.5%) | $2.39 M(-16.5%) |
| Sept 2022 | - | $2.87 M(+10.7%) |
| June 2022 | - | $2.59 M(-12.4%) |
| Mar 2022 | - | $2.96 M(-16.6%) |
| Dec 2021 | $3.54 M(+35.7%) | $3.54 M(+2.5%) |
| Sept 2021 | - | $3.46 M(+27.1%) |
| June 2021 | - | $2.72 M(-2.8%) |
| Mar 2021 | - | $2.80 M(+7.1%) |
| Dec 2020 | $2.61 M(+7.6%) | $2.61 M(-17.2%) |
| Sept 2020 | - | $3.15 M(-7.9%) |
| June 2020 | - | $3.42 M(-2.7%) |
| Mar 2020 | - | $3.52 M(+45.0%) |
| Dec 2019 | $2.43 M(+2.9%) | $2.43 M(+20.8%) |
| Sept 2019 | - | $2.01 M(-27.7%) |
| June 2019 | - | $2.78 M(+101.5%) |
| Mar 2019 | - | $1.38 M(-41.5%) |
| Dec 2018 | $2.36 M(+151.5%) | $2.36 M(+229.0%) |
| Sept 2018 | - | $717.00 K(-39.3%) |
| June 2018 | - | $1.18 M(+68.0%) |
| Mar 2018 | - | $703.00 K(-25.1%) |
| Dec 2017 | $938.00 K(-41.1%) | $938.00 K(+84.6%) |
| Sept 2017 | - | $508.00 K(-32.4%) |
| June 2017 | - | $752.00 K(-29.3%) |
| Mar 2017 | - | $1.06 M(-33.2%) |
| Dec 2016 | $1.59 M(-43.1%) | $1.59 M(-5.6%) |
| Sept 2016 | - | $1.69 M(-4.0%) |
| June 2016 | - | $1.76 M(-61.3%) |
| Mar 2016 | - | $4.55 M(+62.5%) |
| Dec 2015 | $2.80 M(+21.8%) | $2.80 M(+44.7%) |
| Sept 2015 | - | $1.93 M(-27.3%) |
| June 2015 | - | $2.66 M(-1.7%) |
| Mar 2015 | - | $2.71 M(+17.9%) |
| Dec 2014 | $2.30 M(-33.1%) | $2.30 M(-5.2%) |
| Sept 2014 | - | $2.42 M(+28.9%) |
| June 2014 | - | $1.88 M(-25.6%) |
| Mar 2014 | - | $2.53 M(-26.4%) |
| Dec 2013 | $3.43 M(+194.0%) | $3.43 M(+56.0%) |
| Sept 2013 | - | $2.20 M(+30.5%) |
| June 2013 | - | $1.69 M(+15.5%) |
| Mar 2013 | - | $1.46 M(+25.1%) |
| Dec 2012 | $1.17 M(+4.5%) | $1.17 M(+64.8%) |
| Sept 2012 | - | $709.00 K(-20.4%) |
| June 2012 | - | $890.90 K(+47.9%) |
| Mar 2012 | - | $602.50 K(-46.1%) |
| Dec 2011 | $1.12 M(+132.7%) | $1.12 M(+13.8%) |
| Sept 2011 | - | $982.50 K(-33.0%) |
| June 2011 | - | $1.47 M(+53.0%) |
| Sept 2008 | - | $958.50 K(+53.8%) |
| June 2008 | - | $623.10 K(+5.6%) |
| Mar 2008 | - | $590.00 K(+22.8%) |
| Dec 2007 | $480.40 K | $480.40 K(+8.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2007 | - | $442.20 K(+2.1%) |
| June 2007 | - | $433.30 K(-21.7%) |
| Mar 2007 | - | $553.40 K(+28.2%) |
| Dec 2006 | $431.70 K(-23.8%) | $431.70 K(+36.9%) |
| Sept 2006 | - | $315.40 K(+13.1%) |
| June 2006 | - | $278.90 K(-6.0%) |
| Mar 2006 | - | $296.60 K(-47.7%) |
| Dec 2005 | $566.60 K(+105.8%) | $566.60 K(+140.9%) |
| Sept 2005 | - | $235.20 K(-11.8%) |
| June 2005 | - | $266.60 K(-0.5%) |
| Mar 2005 | - | $267.90 K(-2.7%) |
| Dec 2004 | $275.30 K(-32.7%) | $275.30 K(+110.0%) |
| Sept 2004 | - | $131.10 K(-11.3%) |
| June 2004 | - | $147.80 K(-20.2%) |
| Mar 2004 | - | $185.20 K(-54.7%) |
| Dec 2003 | $408.90 K(+14.2%) | $408.90 K(+63.8%) |
| Sept 2003 | - | $249.70 K(-21.4%) |
| June 2003 | - | $317.50 K(-26.0%) |
| Mar 2003 | - | $428.80 K(+19.8%) |
| Dec 2002 | $358.00 K(+15.7%) | $358.00 K(+28.8%) |
| Sept 2002 | - | $278.00 K(-21.8%) |
| June 2002 | - | $355.60 K(+87.6%) |
| Mar 2002 | - | $189.60 K(-38.7%) |
| Dec 2001 | $309.30 K(-14.0%) | $309.30 K(+202.6%) |
| Sept 2001 | - | $102.20 K(-69.1%) |
| June 2001 | - | $330.60 K(+142.4%) |
| Mar 2001 | - | $136.40 K(-62.1%) |
| Dec 2000 | $359.70 K(-39.6%) | $359.70 K(+215.8%) |
| Sept 2000 | - | $113.90 K(-63.0%) |
| June 2000 | - | $308.20 K(+141.9%) |
| Mar 2000 | - | $127.40 K(-78.6%) |
| Dec 1999 | $595.50 K(+197.8%) | $595.50 K(+19.1%) |
| Sept 1999 | - | $500.00 K(+66.7%) |
| June 1999 | - | $300.00 K(0.0%) |
| Mar 1999 | - | $300.00 K(+200.0%) |
| Dec 1998 | $200.00 K(0.0%) | - |
| Sept 1998 | - | $100.00 K(-50.0%) |
| June 1998 | - | $200.00 K(-33.3%) |
| June 1998 | $200.00 K(0.0%) | - |
| Mar 1998 | - | $300.00 K(0.0%) |
| Dec 1997 | - | $300.00 K(+50.0%) |
| Sept 1997 | - | $200.00 K(0.0%) |
| June 1997 | $200.00 K(+100.0%) | $200.00 K(+100.0%) |
| Mar 1997 | - | $100.00 K(-66.7%) |
| Dec 1996 | - | $300.00 K(+50.0%) |
| Sept 1996 | - | $200.00 K(+100.0%) |
| June 1996 | $100.00 K(-66.7%) | $100.00 K(0.0%) |
| Sept 1995 | - | $100.00 K(-66.7%) |
| June 1995 | $300.00 K(+50.0%) | $300.00 K(+200.0%) |
| Mar 1995 | - | $100.00 K(0.0%) |
| Dec 1994 | - | $100.00 K(0.0%) |
| Sept 1994 | - | $100.00 K(0.0%) |
| Mar 1994 | - | $100.00 K(0.0%) |
| Dec 1993 | - | $100.00 K(0.0%) |
| Dec 1992 | - | $100.00 K(0.0%) |
| Sept 1992 | - | $100.00 K(-50.0%) |
| June 1992 | $200.00 K | $200.00 K(0.0%) |
| Mar 1992 | - | $200.00 K |
FAQ
- What is Lineage Cell Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual accounts payable year-on-year change?
- What is Lineage Cell Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly accounts payable year-on-year change?
What is Lineage Cell Therapeutics annual accounts payable?
The current annual accounts payable of LCTX is $2.05 M
What is the all time high annual accounts payable for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual accounts payable is $3.54 M
What is Lineage Cell Therapeutics annual accounts payable year-on-year change?
Over the past year, LCTX annual accounts payable has changed by -$343.00 K (-14.33%)
What is Lineage Cell Therapeutics quarterly accounts payable?
The current quarterly accounts payable of LCTX is $1.60 M
What is the all time high quarterly accounts payable for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly accounts payable is $4.55 M
What is Lineage Cell Therapeutics quarterly accounts payable year-on-year change?
Over the past year, LCTX quarterly accounts payable has changed by -$831.00 K (-34.20%)